Home Top Movers Lineage Cell Therapeutics Inc. (LCTX) stock shows an incline. Why?

Lineage Cell Therapeutics Inc. (LCTX) stock shows an incline. Why?

Lineage Cell Therapeutics, Inc. (LCTX), a clinical-stage biotechnology company specializing to develop allogeneic cell therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and assisting the body in detecting and fighting cancer, reported financial and operating report for the first quarter of 2021.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

At last check in premarket trading, the share price of Lineage Cell Therapeutics Inc. (LCTX) had a slight increase of 0.44%. Shares of the company fluctuated between $2.21 and $2.39 throughout the day. Over the past three months, the stock has lost -24.67%, while over the past six months, it has added 60.28%. Further, the company has a current market of $350.80 million with outstanding shares that stood at 158.72 million.

5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored

Read More

First Quarter Financial Report

Lineage Cell Therapeutic’s revenue was produced mainly from research grants, royalties, and licensing fees. Accumulated revenue generated for the three months completed on March 31, 2021, was almost $0.4 million, representing a decline of $0.1 million from $0.5 million for the same quarter in the previous year. The decline was driven by an approximately $0.2 million reduction in grant income, which was primarily due to the completion of SBIR grant-related activities, driven by a $0.1 million increment in royalty-related revenues.

Operating expenses consisted of research and development (R&D) expenses and general and administrative (G&A) expenses. Total operating expenses for the quarter completed on March 31, 2021, was $7.3 million, depicting a decline of $0.6 million in comparison to $7.9 million for the same quarter the prior year.

R&D expenses for the first quarter of 2021 were $3.4 million, representing an increment of almost $0.1 million versus $3.3 million for the same quarter last year. The overall increment was primarily due to an increase of $0.5 million and $0.4 million in VAC and OPC1 program expenses, and a net decline of $0.8 million in OpRegen and various other ophthalmic application expenses, offset by variations in the timing of manufacturing activities.

Loss from operations in the first quarter of 2021 was almost $7.0 million, depicting a decline of $0.4 million in comparison to $7.4 million for the first quarter of the prior year.

The net loss accredited to Lineage for the first quarter of 2021 was $1.4 million, or $0.01 per share, versus a net loss accredited to Lineage of $8.4 million, or $0.06 per share, in the same quarter of the previous year.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Conclusion

Lineage Cell Therapeutics produced a better-than-expected financial report. Furthermore, an enhanced board of directors combined with Worldwide License Agreement Secured for a Cancer Immunotherapy may provide differentiation for the company and potentially increase investor expectation for LCTX.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Can-Fite BioPharma Inc. (CANF) stock soars during current market. Why so?

Can-Fite BioPharma Inc. (NASDAQ: CANF) stock gained by 4.42% in the current market trading session. Can-Fite BioPharma Ltd. is a medication research company in...

UXIN stock surges during current market. Here’s to know why?

Uxin Ltd. (NASDAQ: UXIN) stock gains by 14.67% at last check during current market trading. In China, Uxin Limited is a prominent online used...

Opgen Inc. (OPGN) stock surged during pre-market session. What’s driving it high?

Opgen Inc. (NASDAQ: OPGN) stock declined by 1.84% at the last close whereas the OPGN stock price gains by 22.07% in the pre-market trading...

Vista Gold Corp. (VGZ) stock soars during pre-market trading. Here’s what you should know

Vista Gold Corp. (NASDAQ: VGZ) stock gained by 17.65% in the pre-market trading session. Vista is a project developer with a gold rating. The...

Novan Inc. (NOVN) stock soars during pre-market trading. What’s driving it high?

Novan Inc. (NASDAQ: NOVN) stock gained by 62.39% at last close whereas the NOVN stock price surged by 0.82% in the pre-market trading session....

Can-Fite BioPharma Inc. (CANF) stock soars during current market. Why so?

Can-Fite BioPharma Inc. (NASDAQ: CANF) stock gained by 4.42% in the current market trading session. Can-Fite BioPharma Ltd. is a medication research company in...

UXIN stock surges during current market. Here’s to know why?

Uxin Ltd. (NASDAQ: UXIN) stock gains by 14.67% at last check during current market trading. In China, Uxin Limited is a prominent online used...

Avenue Therapeutics Inc. (ATXI) stock plunged during pre-market trading. What’s behind this?

Avenue Therapeutics Inc. (NASDAQ: ATXI) stock declined by 28.27% at last close while the ATXI stock price falls during pre-market as well, by 8.94%....

Related News

Aptinyx Inc. (APTX) stock fell during after-hour. Here’s to know why?

Aptinyx Inc. (NASDAQ: APTX) stock declined by 0.29% at last close while the APTX stock price has been observed falling more during the after-hour...

Document Security System Inc. (DSS) stock plunged during after-hour session. Here’s to know the update

Document Security System Inc. (NASDAQ: DSS) stock declined by 6.76% at last close while the DSS stock price falls by 18.48% in the after-hours...

RAPT Therapeutics Inc. (RAPT) stock soars during current market trading. Stated below is the update

RAPT Therapeutics Inc. (NASDAQ: RAPT) stock gained by 85.46% in the current market trading. RAPT Therapeutics is a clinical-stage immunology-based pharmaceutical business focusing on...

Why Enochian Biosciences, Inc. (ENOB) stock Skyrocketed today?

Shares of the Enochian Biosciences, Inc. (ENOB) stock had skyrocketed today on June 14, 2021, following the announcement of FDA acceptance of Pre-IND request...

Why is Aptose Biosciences Inc. (APTO) stock gaining today?

Shares of the Aptose Biosciences Inc. (APTO) stock were gaining in the pre-market session today on June 14, 2021, despite no recent activity by...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam